Maridebart Cafraglutide vs Tirzepatide (2026): GIPR Antagonism vs GIPR Agonism in Obesity Research
MariTide vs tirzepatide: one blocks GIPR, one activates it, yet both hit about 20% weight loss (52-week Phase 2 vs 72-week SURMOUNT-1). See how they compare.
Research reference only. The information in this article is a summary of peer-reviewed scientific literature. It does not constitute medical advice and is not intended to guide human use. See our full disclaimer.
Maridebart cafraglutide vs tirzepatide is one of the most direct tests of the "GIP paradox" in obesity research: one investigational molecule blocks the glucose-dependent insulinotropic polypeptide receptor (GIPR) while the other activates it, yet both have produced roughly 20% mean body weight reductions in clinical trials. This comparison summarizes the mechanism, published trial data, dosing intervals, and regulatory status of each compound as of October 2026.
Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.
Quick Answer: Maridebart cafraglutide (MariTide, AMG 133) pairs GLP-1 receptor agonism with GIP receptor antagonism in a once-monthly antibody-peptide conjugate that is still in Phase 3, while tirzepatide is a once-weekly peptide that activates both GLP-1 and GIP receptors and already holds FDA approval. Phase 2 data for maridebart cafraglutide (up to ~20% at 52 weeks) and Phase 3 SURMOUNT-1 data for tirzepatide (20.9% at 72 weeks, highest dose) fall in a similar range despite opposite GIPR pharmacology.
TL;DR:
- Maridebart cafraglutide antagonizes GIPR; tirzepatide agonizes it. Both are GLP-1 receptor agonists.
- MariTide Phase 2 (NEJM 2025, PMID 40549887): up to ~20% weight reduction at 52 weeks without a plateau.
- Tirzepatide SURMOUNT-1 (NEJM 2022, PMID 35658024): mean 20.9% reduction at 72 weeks on the 15 mg arm.
- Dosing interval is the clearest practical difference: monthly or less often vs once weekly.
- Tirzepatide is FDA approved; maridebart cafraglutide is investigational, with Phase 3 MARITIME trials ongoing.
| Attribute | Maridebart cafraglutide | Tirzepatide |
|---|---|---|
| Developer | Amgen | Eli Lilly |
| Development stage | Phase 3 (MARITIME program) | Approved (US, EU and others) |
| GIP receptor action | Antagonist | Agonist |
| Headline weight-loss figure | Up to ~20% at 52 weeks (Phase 2) | 20.9% at 72 weeks (Phase 3, 15 mg) |
| Dosing interval studied | Every 4 weeks or less often | Once weekly |
Maridebart cafraglutide: mechanism and evidence base
Maridebart cafraglutide is a peptide-antibody conjugate. A fully human monoclonal antibody directed against the GIP receptor serves as the backbone, and two GLP-1 receptor-agonist peptides are chemically linked to it. The antibody portion blocks GIPR signaling, while the attached peptides activate the GLP-1 receptor. Because the molecule carries antibody pharmacokinetics, its reported half-life is roughly three weeks, which is what allows trial protocols to space doses a month or more apart. Full chemistry and trial cross-references are maintained on the maridebart cafraglutide library profile.
The primary human dataset is the Phase 2 dose-ranging trial published in the New England Journal of Medicine in June 2025 (PMID 40549887; NCT05669599). The trial randomized 592 adults with obesity or overweight, 465 without diabetes and 127 with type 2 diabetes, to placebo or one of several maridebart cafraglutide regimens. Investigators administered doses subcutaneously every four weeks, with some arms extended to every eight weeks. At 52 weeks, participants without diabetes lost up to approximately 20% of body weight versus 2.6% with placebo, and the weight curve had not plateaued. Participants with type 2 diabetes lost up to approximately 17% versus 1.4% with placebo, with HbA1c reductions of up to 2.2 percentage points.
Gastrointestinal adverse events, mainly nausea and vomiting, were the most frequently reported effects and clustered around the first dose. Amgen has since reported that a three-step dose escalation reduced those rates compared with the two-step escalation used in earlier studies, though the full dataset for that change has not been published in a peer-reviewed journal.
The Phase 3 MARITIME program includes MARITIME-1 (NCT06858839, obesity without diabetes), MARITIME-2 (NCT06858878, obesity with type 2 diabetes), a cardiovascular outcomes trial (NCT07037433), an obstructive sleep apnea study (NCT07225686), an elevated liver fat study (NCT07441252) and a Japan obesity study (NCT06987695). In April 2026 Amgen also described a 300-participant switch study evaluating transition from weekly incretin agonists. No Phase 3 topline results had been reported as of this writing; current statuses can be followed on the clinical trial tracker.
Tirzepatide: mechanism and evidence base
Tirzepatide is a 39-amino-acid synthetic peptide built on the native GIP sequence and modified with a C20 fatty diacid side chain that binds albumin. That modification gives a half-life of roughly five days and supports once-weekly subcutaneous dosing. Pharmacologically it is described as an imbalanced dual agonist: it activates the GIP receptor with potency similar to native GIP, while its activity at the GLP-1 receptor is weaker and biased toward cAMP signaling over beta-arrestin recruitment. Profile data is available on the tirzepatide library page.
The pivotal obesity dataset is SURMOUNT-1 (Jastreboff et al., New England Journal of Medicine, 2022; PMID 35658024; NCT04184622). The trial randomized 2,539 adults with obesity or overweight and without diabetes to 5 mg, 10 mg or 15 mg of tirzepatide or placebo, administered subcutaneously once weekly for 72 weeks. Mean body weight reductions were 15.0%, 19.5% and 20.9% in the three dose groups, compared with 3.1% with placebo. As with maridebart cafraglutide, gastrointestinal events were the most common adverse effects and occurred mainly during dose escalation.
Real-world data adds a longer horizon. A 2026 single-center cohort study from the United Arab Emirates (PMID 42029986) followed 100 adults with obesity and without type 2 diabetes. Median weight reduction was 8.1% in participants treated for one year or less and 22.6% in those treated for more than one year, and the authors reported that "tirzepatide showed greater cumulative benefits across CKM syndrome outcomes during the second treatment year." Observational designs of this kind cannot separate drug effect from adherence selection, but they help frame what sustained exposure looks like outside a trial.
Why GIPR agonism and antagonism can both reduce weight
The two compounds sit on opposite sides of a long-running question in incretin biology. Genetic studies in humans and mice linked reduced GIPR signaling to lower body mass, which motivated the antagonist strategy behind maridebart cafraglutide. In parallel, pharmacology studies found that adding GIP agonism to GLP-1 agonism enhanced weight loss and improved tolerability, which motivated tirzepatide.
One proposed explanation is that chronic GIPR agonism leads to receptor desensitization and internalization, so a sustained agonist may functionally behave like a partial antagonist over time. If that hypothesis holds, both molecules may converge on reduced net GIPR signaling in some tissues while differing in others, such as adipose tissue lipid handling or central nausea pathways. The question remains unresolved, and no head-to-head human trial comparing the two compounds has been published. Related receptor biology for a triple agonist is discussed on the retatrutide library profile, and the single-pathway GLP-1 reference compound is covered on the semaglutide profile.
Side-by-side comparison
| Attribute | Maridebart cafraglutide | Tirzepatide |
|---|---|---|
| Development code | AMG 133 | LY3298176 |
| Molecular format | Anti-GIPR antibody conjugated to two GLP-1 agonist peptides | Single 39-amino-acid acylated peptide |
| GLP-1 receptor | Agonist | Agonist (weaker, cAMP-biased) |
| GIP receptor | Antagonist | Agonist |
| Approximate half-life | ~3 weeks | ~5 days |
| Dosing interval studied | Every 4 to 8 weeks | Once weekly |
| Route | Subcutaneous | Subcutaneous |
| Key obesity trial | Phase 2, 592 participants, 52 weeks | SURMOUNT-1, 2,539 participants, 72 weeks |
| Headline weight-loss figure | Up to ~20% (no diabetes) | 20.9% (15 mg arm) |
| Placebo comparator | 2.6% | 3.1% |
| Regulatory status | Investigational | FDA approved |
Cross-trial comparisons carry important caveats. The two trials differ in duration, population, dose escalation and statistical estimands, so the similar headline figures should not be read as equivalence. Half-life values can be visualized alongside other incretin compounds on the peptide half-life chart.
Differential research applications
Researchers studying GIPR biology use the pair as natural mechanistic opposites. Maridebart cafraglutide is the more relevant reference when the question involves receptor blockade, antibody-conjugate pharmacokinetics, or how extended dosing intervals affect adherence and weight maintenance. The Phase 2 observation that weight loss had not plateaued at 52 weeks (PMID 40549887) makes longer follow-up a central research question for the Phase 3 program.
Tirzepatide is the more common reference compound when a study needs an approved dual agonist with a large, mature evidence base. SURMOUNT-1 (PMID 35658024) and subsequent trials provide dose-response data across multiple populations, and the real-world cohort data (PMID 42029986) allow comparison between trial and clinical-practice outcomes. Because tirzepatide is now the active comparator in many pipeline trials, investigational compounds, including maridebart cafraglutide in its switch study, are increasingly measured against it.
Regulatory and compounding status
Tirzepatide is approved by the FDA for type 2 diabetes (2022) and chronic weight management (2023), and it holds approvals from the EMA and other regulators. After the FDA removed tirzepatide from its drug shortage list, the period for widespread 503A and 503B compounding of the compound ended, and copies of approved drugs remain subject to restrictions under federal compounding rules.
Maridebart cafraglutide is investigational and has no approval in any jurisdiction. As an antibody-based biologic, it falls outside the 503A bulk drug substance framework entirely; any future approval would come through a Biologics License Application. Amgen's Phase 3 program is expected to report primary completion for its core obesity trials around early 2027.
Cited studies
- PMID 40549887, "Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity, A Phase 2 Trial." (New England Journal of Medicine, 2025). https://doi.org/10.1056/NEJMoa2504214
- PMID 35658024: "Tirzepatide Once Weekly for the Treatment of Obesity." (New England Journal of Medicine, 2022). https://doi.org/10.1056/NEJMoa2206038
- PMID 42029986: "Persistence-Dependent Effectiveness of Tirzepatide on the Cardio-Metabolic-Kidney Syndrome Outcomes in Obesity: Real-World Evidence from the United Arab Emirates." (Diabetes Therapy, 2026). https://doi.org/10.1007/s13300-026-01868-2
Frequently asked questions
Q: What is the difference between maridebart cafraglutide and tirzepatide?
A: Both activate the GLP-1 receptor, but maridebart cafraglutide blocks the GIP receptor while tirzepatide activates it. Maridebart cafraglutide is a monthly antibody-peptide conjugate in Phase 3, whereas tirzepatide is a weekly peptide with FDA approval.
Q: Tirzepatide vs MariTide: which produced more weight loss in trials?
A: The headline figures are similar: up to about 20% at 52 weeks for maridebart cafraglutide in Phase 2 and 20.9% at 72 weeks for the highest tirzepatide dose in SURMOUNT-1. The trials differ in duration, design and population, and no head-to-head study has been published, so a direct ranking is not supported by current data.
Q: Why would blocking and activating the GIP receptor both reduce body weight?
A: Human genetic data linked lower GIPR signaling to lower body mass, while pharmacology studies showed GIP agonism enhancing GLP-1 effects. One hypothesis is that sustained agonism desensitizes the receptor, so both approaches may reduce net GIPR signaling in certain tissues.
Q: How often is maridebart cafraglutide dosed in clinical trials?
A: The Phase 2 trial administered maridebart cafraglutide subcutaneously every four weeks, with some arms every eight weeks. Its antibody backbone gives a half-life of roughly three weeks, compared with about five days for tirzepatide.
Q: When could Phase 3 MARITIME results be reported?
A: Amgen's core obesity trials, MARITIME-1 and MARITIME-2, are expected to reach primary completion around early 2027. No Phase 3 topline data had been released as of October 2026.
See also:
- Maridebart Cafraglutide vs Retatrutide: compares MariTide's GIPR antagonism with a GLP-1/GIP/glucagon triple agonist.
- Retatrutide vs Tirzepatide: how adding glucagon receptor agonism changes the tirzepatide profile.
- Mazdutide vs Tirzepatide: a GLP-1/glucagon dual agonist approved in China compared with tirzepatide.
For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.